CN101190927A - 9-[2-(膦酰甲氧)乙基]腺嘌呤单特戊酰氧甲酯的制备方法 - Google Patents
9-[2-(膦酰甲氧)乙基]腺嘌呤单特戊酰氧甲酯的制备方法 Download PDFInfo
- Publication number
- CN101190927A CN101190927A CNA2006101297862A CN200610129786A CN101190927A CN 101190927 A CN101190927 A CN 101190927A CN A2006101297862 A CNA2006101297862 A CN A2006101297862A CN 200610129786 A CN200610129786 A CN 200610129786A CN 101190927 A CN101190927 A CN 101190927A
- Authority
- CN
- China
- Prior art keywords
- adefovir
- monoester
- preparation
- water
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 25
- -1 pivaloyloxymethyl Chemical group 0.000 title claims description 24
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 title description 8
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 title 1
- 229930024421 Adenine Natural products 0.000 title 1
- 229960000643 adenine Drugs 0.000 title 1
- 229960001997 adefovir Drugs 0.000 claims abstract description 114
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims abstract description 99
- 238000002360 preparation method Methods 0.000 claims abstract description 36
- 239000003513 alkali Substances 0.000 claims abstract description 10
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 238000004440 column chromatography Methods 0.000 claims description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 3
- 235000017550 sodium carbonate Nutrition 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 2
- 235000015320 potassium carbonate Nutrition 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 2
- 239000011707 mineral Substances 0.000 claims 2
- 235000010755 mineral Nutrition 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 239000012046 mixed solvent Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 229910002027 silica gel Inorganic materials 0.000 claims 1
- 239000000741 silica gel Substances 0.000 claims 1
- 229960001866 silicon dioxide Drugs 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 30
- 239000012043 crude product Substances 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 150000003722 vitamin derivatives Chemical class 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229960003205 adefovir dipivoxil Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 150000002240 furans Chemical class 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- GGRHYQCXXYLUTL-UHFFFAOYSA-N chloromethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCl GGRHYQCXXYLUTL-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- OZNYZQOTXQSUJM-UHFFFAOYSA-N n,n'-dicyclohexylmorpholine-4-carboximidamide Chemical compound C1CCCCC1NC(N1CCOCC1)=NC1CCCCC1 OZNYZQOTXQSUJM-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 150000003008 phosphonic acid esters Chemical class 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101297862A CN101190927B (zh) | 2006-11-30 | 2006-11-30 | 9-[2-(膦酰甲氧)乙基]腺嘌呤单特戊酰氧甲酯的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101297862A CN101190927B (zh) | 2006-11-30 | 2006-11-30 | 9-[2-(膦酰甲氧)乙基]腺嘌呤单特戊酰氧甲酯的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101190927A true CN101190927A (zh) | 2008-06-04 |
CN101190927B CN101190927B (zh) | 2012-04-18 |
Family
ID=39486142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006101297862A Expired - Fee Related CN101190927B (zh) | 2006-11-30 | 2006-11-30 | 9-[2-(膦酰甲氧)乙基]腺嘌呤单特戊酰氧甲酯的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101190927B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101812090A (zh) * | 2010-05-10 | 2010-08-25 | 浙江车头制药有限公司 | 一种阿德福韦单酯的制备方法 |
KR101007510B1 (ko) | 2008-10-06 | 2011-01-12 | 주식회사 대희화학 | 아데포버 디피복실의 신규한 제조방법 |
CN101357930B (zh) * | 2008-09-09 | 2011-06-29 | 珠海联邦制药股份有限公司 | 一种阿德福韦酯的制备方法 |
WO2013029199A1 (zh) * | 2011-08-29 | 2013-03-07 | 天津泰普药品科技发展有限公司 | 阿德福韦单酯及其制备方法 |
US9908908B2 (en) | 2012-08-30 | 2018-03-06 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Tenofovir prodrug and pharmaceutical uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0481214T3 (da) * | 1990-09-14 | 1999-02-22 | Acad Of Science Czech Republic | Prolægemidler af phosphonater |
CN1523029A (zh) * | 2003-09-12 | 2004-08-25 | 上海医药工业研究院 | 一种阿德福韦酯新的晶型及其制备方法 |
-
2006
- 2006-11-30 CN CN2006101297862A patent/CN101190927B/zh not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101357930B (zh) * | 2008-09-09 | 2011-06-29 | 珠海联邦制药股份有限公司 | 一种阿德福韦酯的制备方法 |
KR101007510B1 (ko) | 2008-10-06 | 2011-01-12 | 주식회사 대희화학 | 아데포버 디피복실의 신규한 제조방법 |
CN101812090A (zh) * | 2010-05-10 | 2010-08-25 | 浙江车头制药有限公司 | 一种阿德福韦单酯的制备方法 |
CN101812090B (zh) * | 2010-05-10 | 2013-08-14 | 浙江车头制药股份有限公司 | 一种阿德福韦单酯的制备方法 |
WO2013029199A1 (zh) * | 2011-08-29 | 2013-03-07 | 天津泰普药品科技发展有限公司 | 阿德福韦单酯及其制备方法 |
US9908908B2 (en) | 2012-08-30 | 2018-03-06 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Tenofovir prodrug and pharmaceutical uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CN101190927B (zh) | 2012-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101190927B (zh) | 9-[2-(膦酰甲氧)乙基]腺嘌呤单特戊酰氧甲酯的制备方法 | |
CN102584795B (zh) | 一种克里唑替尼的制备方法 | |
CN104024262A (zh) | 埃克替尼和盐酸埃克替尼的制备方法及其中间体 | |
CN104610360A (zh) | 一种富马酸替诺福韦二吡呋酯的制备方法 | |
CN106699756B (zh) | β内酰胺酶抑制剂阿维巴坦的合成方法 | |
CN106349245A (zh) | 一种磷酸西格列汀杂质及其制备方法和用途 | |
CN106749194A (zh) | 一种替匹嘧啶的制备方法 | |
CN103664896B (zh) | 一种抗肿瘤分子靶向药物克里唑替尼的合成工艺方法 | |
CN105566215B (zh) | 一种瑞戈非尼的制备方法 | |
CN100549013C (zh) | 2-氨基-6-氯嘌呤的合成方法 | |
CN111943937A (zh) | 三苯基坎地沙坦的合成方法 | |
KR100976762B1 (ko) | 아데포비어디피복실의 개선된 제조방법 | |
CN102633802B (zh) | 一种合成2-氯-7H-吡咯并[2,3-d]嘧啶的中间体及其制法 | |
CN102199132A (zh) | 2-(2-氨基-4-噻唑)-2(z)-[[(叔丁氧羰基)甲氧]亚氨]乙酸及其盐的制备方法 | |
CN102260298B (zh) | 一种合成1,2,3-O-三乙酰基-5-脱氧-β-D-核糖的方法 | |
CN104341452A (zh) | 富马酸替诺福韦酯杂质的制备方法 | |
CN103588712A (zh) | 一种嘧啶类化合物及其制备方法、和应用 | |
CN102786543A (zh) | 咪唑并[1,2-a]吡啶-6-硼酸频哪醇酯及其衍生物的制备方法 | |
CN108117523B (zh) | 卤代尿嘧啶类化合物的制备方法 | |
CN104860888B (zh) | 阿卡他定中间体及阿卡他定的合成方法 | |
CN107602535A (zh) | 苯甲酸阿格列汀的制备方法 | |
CN103554082B (zh) | 一种合成3-(4-氨基-1-异吲哚酮-2-基)哌啶-2,6-二酮的方法 | |
CN107033090A (zh) | 一种1,2,3,4‑四氢噌啉的制备方法 | |
CN103819524B (zh) | 3’-氟取代嘌呤核苷类似物、其制备方法及其应用 | |
CN110483575B (zh) | 一种阿德福韦酯的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: TASLY HOLDING GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY GROUP CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee after: TASLY HOLDING GROUP Co.,Ltd. Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tianjin Tasly Group Co.,Ltd. |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20080604 Assignee: JIANGSU TASLY DIYI PHARMACEUTICAL Co.,Ltd. Assignor: TASLY HOLDING GROUP Co.,Ltd. Contract record no.: 2015320000317 Denomination of invention: Method for preparing 9-[2- (phosphine) ethyl] adenine mono amyl methyl ester Granted publication date: 20120418 License type: Exclusive License Record date: 20150508 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160727 Address after: 223003 Jiangsu Huaian Qingpu Industrial Park, Chaoyang Road No. 168 Patentee after: JIANGSU TASLY DIYI PHARMACEUTICAL Co.,Ltd. Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: TASLY HOLDING GROUP Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120418 Termination date: 20211130 |
|
CF01 | Termination of patent right due to non-payment of annual fee |